{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:01:47Z","timestamp":1760234507166,"version":"build-2065373602"},"reference-count":67,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: Type 2 diabetes mellitus (T2DM) is the main cause of chronic kidney disease (CKD). In Greece, in a population from hospital-based diabetes clinics (n = 1759), the overall prevalence of diabetic chronic kidney disease (DCKD) was 45% including mild, moderate, and severe CKD. The aim of this study was to describe and analyze how T2DM patients with mild-to-severe CKD are managed by diabetologists in Greece and assess the achievement rates in glycemic, blood pressure and low-density lipoprotein-cholesterol (LDL-C) control. (2) Methods: This cross-sectional multicenter study took place from June 2015 to March 2016 and collected data from diabetes centers in public hospitals all over Greece. (3) Results: With regard to the anti-diabetes treatment, most participants were on metformin, DPP-4 (Dipeptidyl Peptidase-4 inhibitors) inhibitors and insulin. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers were the most prescribed medications for hypertension. For the management of dyslipidemia, most participants were on statins. For patients with DCKD, the levels of HbA1c, blood pressure and LDL-C were 7.2%, 137.7\/76.9 mmHg and 95.9 mg\/dL, respectively (mean values). (4) Conclusions: The outcomes of this study suggest that management of DCKD can be further improved and should be enhanced. These results may contribute to the whole health care system in Greece. In addition, the better understanding of therapeutic strategies used by diabetologists treating these patients offers educational benefits to primary care physicians, which can result in an overall more successful and efficient management of subjects with T2DM and DCKD.<\/jats:p>","DOI":"10.3390\/jcm10102104","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T11:10:06Z","timestamp":1620904206000},"page":"2104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antidiabetic and Other Therapies Used in Subjects with Diabetes and Chronic Kidney Disease in a Hospital-Based Clinic Population in Greece"],"prefix":"10.3390","volume":"10","author":[{"given":"Ilias","family":"Migdalis","sequence":"first","affiliation":[{"name":"Second Medical Department and Diabetes Centre, NIMTS Hospital, 11521 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine and Diabetes Centre, University Hospital of Alexandroupolis, Democritus University of Thrace, 68132 Alexandroupolis, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ioannidis","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and Diabetes Centre, General Hospital of Nea Ionia Konstantopoulio-Patision, 14233 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexios","family":"Sotiropoulos","sequence":"additional","affiliation":[{"name":"Third Medical Department and Diabetes Centre, Hospital of Nikaia, 18454 Piraeus, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Raptis","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-9936","authenticated-orcid":false,"given":"George","family":"Dimitriadis","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Hellenic Diabetic Nephropathy Study (HDNS)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108243","DOI":"10.1016\/j.diabres.2020.108243","article-title":"The prevalence of diabetic chronic kidney disease in adult Greek subjects with type 2 diabetes mellitus: A series from hospital-based diabetes clinics","volume":"166","author":"Migdalis","year":"2020","journal-title":"Diabetes Res. Clin. Pr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.kint.2018.12.025","article-title":"Blood pressure in chronic kidney disease: Conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Cheung","year":"2019","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jdi.12953","article-title":"Discordance in risk factors for the progression of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes mellitus","volume":"10","author":"Song","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_6","first-page":"5","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Eknoyan","year":"2013","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1573399811666150331160534","article-title":"The effects of glucose-lowering therapies on diabetic kidney disease","volume":"11","author":"Agrawal","year":"2015","journal-title":"Curr. Diabetes Rev."},{"key":"ref_8","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) lipid work group. KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","author":"Tonelli","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_10","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.ajkd.2014.09.016","article-title":"Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"65","author":"Ricardo","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"Turner","year":"1998","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1001\/archinternmed.2011.537","article-title":"Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease","volume":"171","author":"Shurraw","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US Commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Guideline Development Group (2015). Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL\/min). Nephrol. Dial. Transplant., 30, 1\u2013142.","DOI":"10.1093\/ndt\/gfv100"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). Introduction: Standards of medical care in diabetes\u20142021. Diabetes Care, 44, S1\u2013S2.","DOI":"10.2337\/dc21-Sint"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 Diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial","volume":"376","author":"Craven","year":"2010","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation (2012). KDOQI clinical practice guideline for diabetes and CKD: 2012 Update. Am. J. Kidney Dis., 60, 850\u2013886.","DOI":"10.1053\/j.ajkd.2012.07.005"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1046\/j.1464-5491.2003.01025.x","article-title":"Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients","volume":"20","author":"Biesenbach","year":"2003","journal-title":"Diabet. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.0894-0959.2004.17346.x","article-title":"Reviews: Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease","volume":"17","author":"Snyder","year":"2004","journal-title":"Semin. Dial."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7326\/0003-4819-68-1-63","article-title":"Carbohydrate metabolism in uremia","volume":"68","author":"Horton","year":"1968","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","article-title":"Frequency of hypoglycemia and its significance in chronic kidney disease","volume":"4","author":"Moen","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clinthera.2007.02.012","article-title":"Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: A retrospective database study","volume":"29","author":"Yurgin","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc12-2258","article-title":"The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010","volume":"36","author":"Casagrande","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diabres.2014.08.002","article-title":"Real life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 394,828 German patients","volume":"106","author":"Wilke","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liatis, S., Papaoikonomou, S., Ganotopoulou, A., Papazafiropoulou, A., Dinos, C., Michail, M., Xilomenos, A., Melidonis, A., and Pappas, S. (2014). Management of type 2 diabetes and its prescription drug cost before and during the economic crisis in Greece: An observational study. BMC Endocr. Disord., 14.","DOI":"10.1186\/1472-6823-14-23"},{"key":"ref_29","first-page":"53","article-title":"The real-life effectiveness and care patterns of type 2 diabetes management in Greece","volume":"126","author":"Pagkalos","year":"2017","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1007\/s13300-020-00935-6","article-title":"Adherence to the national guidelines for follow-up protocol in subjects with type 2 diabetes Mellitus in Greece: The GLANCE study","volume":"11","author":"Papanas","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12902-019-0364-5","article-title":"A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies","volume":"19","author":"Liatis","year":"2019","journal-title":"BMC Endocr. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/640632","article-title":"Glucose lowering therapeutic strategies for type 2 diabetic patients with chronic kidney disease in primary care setting in France: A cross-sectional study","volume":"2013","author":"Grandfils","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2147\/IJGM.S285191","article-title":"Renal outcomes associated with the use of non-insulin antidiabetic pharmacotherapy: A review of current evidence and recommendations","volume":"13","author":"Elnaem","year":"2020","journal-title":"Int. J. Gen. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/ijcp.12640","article-title":"Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: A retrospective cohort study","volume":"69","author":"Ruzafa","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kovesdy, C.P., Isaman, D., Petruski-Ivleva, N., Fried, L., Blankenburg, M., Gay, A., Velentgas, P., and Folkerts, K. (2020). Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: A population cohort study. Clin. Kidney J.","DOI":"10.1093\/ckj\/sfaa200"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diabet.2007.07.001","article-title":"Type 2 diabetes mellitus: Epidemiology, pathophysiology, unmet needs and therapeutical perspectives","volume":"33","author":"Virally","year":"2007","journal-title":"Diabetes Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2337\/diabetes.49.11.1751","article-title":"Triggering and amplifying pathways of regulation of insulin secretion by glucose","volume":"49","author":"Henquin","year":"2000","journal-title":"Diabetes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.14310\/horm.2002.1436","article-title":"Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease","volume":"12","author":"Nogueira","year":"2013","journal-title":"Hormones"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/JOE-17-0516","article-title":"Mechanisms of \u03b2-cell dedifferentiation in diabetes: Recent findings and future research directions","volume":"236","author":"Bensellam","year":"2018","journal-title":"J. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e001076","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: A cohort study from the Swedish National Diabetes Register","volume":"2","author":"Svensson","year":"2012","journal-title":"BMJ Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ki.2014.19","article-title":"Metformin and other antidiabetic agents in renal failure patients","volume":"87","author":"Lalau","year":"2015","journal-title":"Kidney Int."},{"key":"ref_43","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"2010","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4065\/mcp.2010.0713","article-title":"Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus","volume":"86","author":"Bakris","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-2125.2003.01785.x","article-title":"The pharmacokinetics of pioglitazone in patients with impaired renal function","volume":"55","author":"Budde","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e0165750","DOI":"10.1371\/journal.pone.0165750","article-title":"Renal Outcomes of pioglitazone compared with acarbose in diabetic patients: A randomized controlled study","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1423191","article-title":"Renal protective effect of DPP-4 inhibitors in type 2 diabetes mellitus patients: A cohort study","volume":"2016","author":"Kim","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): A multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 Inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Cupisti, A., Giannese, D., Moriconi, D., D\u2019Alessandro, C., Torreggiani, M., and Piccoli, G.B. (2020). Nephroprotection by SGLT2i in CKD patients: May It be modulated by low-protein plant-based Diets?. Front. Med., 7.","DOI":"10.3389\/fmed.2020.622593"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1475-2840-12-62","article-title":"The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes","volume":"12","author":"Hanefeld","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on diabetic nephropathy: Core Curriculum 2018","volume":"71","author":"Umanath","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"ref_59","first-page":"OC11","article-title":"Diabetic kidney disease and hypertension: A true love story","volume":"10","author":"Verma","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e000154","DOI":"10.1136\/bmjdrc-2015-000154","article-title":"Understanding CKD among patients with T2DM: Prevalence, temporal trends, and treatment patterns\u2014NHANES 2007\u20132012","volume":"4","author":"Wu","year":"2016","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2147\/IJGM.S255858","article-title":"Study on risk factors of diabetic nephropathy in obese patients with type 2 diabetes mellitus","volume":"ume 13","author":"Hu","year":"2020","journal-title":"Int. J. Gen. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","article-title":"2007 ESH-ESC practice guidelines for the management of arterial hypertension","volume":"25","author":"Mancia","year":"2007","journal-title":"J. Hypertens."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1900\/RDS.2013.10.88","article-title":"Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients","volume":"10","author":"Chen","year":"2013","journal-title":"Rev. Diabet. Stud."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The treating to new targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/10\/2104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:00:34Z","timestamp":1760162434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/10\/2104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["jcm10102104"],"URL":"https:\/\/doi.org\/10.3390\/jcm10102104","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,5,13]]}}}